Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - A retrospective analysis: JMTO LC03-02

被引：19
作者：
Nakagawa M. [1 ,2 ,5 ]
Nishimura T. [1 ,5 ]
Teramukai S. [1 ,5 ]
Tada H. [1 ,5 ]
Tanaka F. [3 ,5 ]
Yanagihara K. [4 ,5 ]
Furuse K. [5 ]
Wada H. [2 ,5 ]
Fukushima M. [1 ,5 ,6 ]
机构：
[1] Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto
[2] Department of Thoracic Surgery, Kyoto University, Kyoto
[3] Department of Thoracic Surgery, Hyogo College of Medicine, Nishinomiya
[4] Department of Translational Clinical Oncology, Kyoto University, Kyoto
[5] Japan Multinational Trial Organization, Kyoto
[6] Translational Research Informatics Center, Kobe
来源：
BMC Research Notes | / 2卷 / 1期
关键词：
Gefitinib; Interstitial Lung Disease; Absolute Neutrophil Count; Prior Chemotherapy; Response Proportion;
D O I：
10.1186/1756-0500-2-157
中图分类号：
学科分类号：
摘要：
Background. In Japan, high incidences of interstitial lung disease (ILD) and ILD-related deaths have been reported among gefitinib-treated patients with non-small cell lung cancer (NSCLC). We investigated the efficacy of gefitinib, the incidence of ILD and risk factors for ILD in these patients. Findings. We obtained patient data retrospectively using questionnaires sent to 22 institutions. We asked for demographic and clinical data on NSCLC patients for whom gefitinib treatment had begun between July 2002 and February 2003. Data from a total of 526 patients were analyzed. The patient characteristics were as follows: 64% male, 69% with adenocarcinoma, 61% with a performance score of 0-1, and 5% with concurrent interstitial pneumonitis. The objective response proportion was 80/439 (18.2%; 95% CI: 14.7-22.0). ILD developed in 17 patients (3.2%; 95% CI 1.9-5.1%), of whom 7 died. According to multivariate analysis, female sex, history of prior chemotherapy, low absolute neutrophil count before gefitinib treatment, and adenocarcinoma histology were associated with response to gefitinib treatment. None of the factors we evaluated were associated with the development of ILD. Conclusion. The results of this study are consistent with previously published values for treatment response proportions and incidence of ILD during gefitinib treatment in Japanese patients. Future studies should be aimed at identifying factors indicating that a patient has a high probability of receiving benefit from gefitinib and a low risk of developing ILD. © 2009 Nakagawa et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 24 条
[1]  
Samet J.M., Epidemiology of Lung Cancer, (1994)
[2]  
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials, BMJ, 311, pp. 899-909, (1995)
[3]  
Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., Jiroutek M., Johnson D., Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial, J Clin Oncol, 18, pp. 623-631, (2000)
[4]  
Rudd R.M., Gower N.H., Spiro S.G., Eisen T.G., Harper P.G., Littler J.A., Hatton M., Johnson P.W., Martin W.M., Rankin E.M., James L.E., Gregory W.M., Qian W., Lee S.M., Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIb or IV non-small-cell lung cancer: A phase III randomized study of the London Lung Cancer Group, J Clin Oncol, 23, pp. 142-153, (2005)
[5]  
Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., Kalman L., Miller V., Lee J.S., Moore M., Gandara D., Karp D., Vokes E., Kris M., Kim Y., Gamza F., Hammershaimb L., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens, Journal of Clinical Oncology, 18, 12, pp. 2354-2362, (2000)
[6]  
Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., Levitan N., Gressot L., Vincent M., Burkes R., Coughlin S., Kim Y., Berille J., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy, Journal of Clinical Oncology, 18, 10, pp. 2095-2103, (2000)
[7]  
Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., Kaye S.B., Gianni L., Harris A., Bjork T., Averbuch S.D., Feyereislova A., Swaisland H., Rojo F., Albanell J., Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types, Journal of Clinical Oncology, 20, 21, pp. 4292-4302, (2002)
[8]  
Herbst R.S., Maddox A.-M., Rothenberg M.L., Small E.J., Rubin E.H., Baselga J., Rojo F., Hong W.K., Swaisland H., Averbuch S.D., Ochs J., LoRusso P.M., Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial, Journal of Clinical Oncology, 20, 18, pp. 3815-3825, (2002)
[9]  
Nakagawa K., Tamura T., Negoro S., Kudoh S., Yamamoto N., Yamamoto N., Takeda K., Swaisland H., Nakatani I., Hirose M., Dong R.P., Fukuoka M., Phase i pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors, Ann Oncol, 14, pp. 922-930, (2003)
[10]  
Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., Eek R., Horai T., Noda K., Takata I., Smit E., Averbuch S., MacLeod A., Feyereislova A., Dong R.P., Baselga J., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer, J Clin Oncol, 21, pp. 2237-2246, (2003)
123